Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4646 · 1 trial · 1 indication
Percentage of participants with one or more AEs
Percentage of participants who discontinued study medication due to an AE
Time course of plasma HIV-1 RNA viral load decline.
| Arm | Type | Description |
|---|---|---|
| MK-4646 Panel A | EXPERIMENTAL | MK-4646 160 mg every 24 hours (q24h) for 7 days |
| MK-4646 Panel B | EXPERIMENTAL | MK-4646 ≤460 mg q24h for 7 days |
| MK-4646 Panel C | EXPERIMENTAL | MK-4646 ≤460 mg q24h for 7 days |
| MK-4646 Panel D | EXPERIMENTAL | MK-4646 ≤460 mg every 12 hours (q12h) for 7 days |
| Name | Type | Description |
|---|---|---|
| MK-4646 | DRUG | MK-4646 in capsular form administered orally |
Inclusion Criteria: * Other than having HIV-1, is in good health * Is antiretroviral therapy (ART)-naïve * If ART-experienced has not received any antiretroviral therapy within 60 days (or 5 half-lives, whichever is longer) prior to screening * Is willing to receive no other ART prior to Day 8 post...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
MK-4646 is an investigational small molecule being studied for the treatment of HIV Infection, specifically Human Immunodeficiency Virus Type 1 (HIV-1). It is in Phase 1 clinical development and has not been approved for any indication. The completed Phase 1 trial enrolled adults aged 18 years and older living with HIV-1.
MK-4646 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the Phase 1 clinical program evaluating MK-4646 in participants with HIV-1 infection.
MK-4646 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency for the treatment of HIV Infection.
MK-4646 has been evaluated in one completed Phase 1 trial, NCT07042945, titled MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003). The trial enrolled 15 participants across Moldova and Romania, was randomized and controlled, and included adults aged 18 years and older.
Yes, MK-4646 and MK4646 refer to the same investigational compound. MK-4646 is the hyphenated form of the name, while MK4646 is the unhyphenated form. Both names are used interchangeably in reference to the Merck HIV-1 candidate in Phase 1 development.